RxDoctor Payments DataLook up a doctor →

Keith Schluterman, MD

Neurology · Conway, ARNPI 1053318147

Payments from drug & device makers

$66,747in general payments, 2019–2025

Across 1,668 payments — averaging $40.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$23K
  • Pfizer$6K
  • Biohaven Pharmaceutical Holding Company Ltd.$6K
  • Acorda Therapeutics, Inc$3K
  • Biogen$2K
  • AbbVie$2K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$1,8253%
  • Speaking & faculty fees$34,16451%
  • Travel & lodging$1320%
  • Food & beverage$30,20145%
  • Education$4251%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.56$23,115
Pfizer90$5,937
Biohaven Pharmaceutical Holding Company Ltd.45$5,926
Acorda Therapeutics, Inc13$2,913
Biogen90$2,012
AbbVie(2 entities)142$1,802
Jazz Pharmaceuticals Inc.82$1,797
Novartis85$1,673
Amgen65$1,525
EMD Serono, Inc.77$1,356
UCB, Inc.44$1,341
SK Life Science, Inc.59$1,326
Lundbeck LLC66$1,252
MDD US Operations, LLC51$1,224
Amneal Pharmaceuticals LLC60$1,120
Kyowa Kirin, Inc.47$956
Neurocrine Biosciences, Inc.60$924
Supernus Pharmaceuticals, Inc.42$775
CSL Behring37$736
Sanofi34$733
AstraZeneca(2 entities)42$726
Eisai Inc.36$713
Lilly USA, LLC54$708
Upsher-smith Laboratories LLC38$581
Inspire Medical Systems, Inc.5$573
Acadia Pharmaceuticals Inc30$569
Harmony Biosciences LLC23$499
Teva Pharmaceuticals USA, Inc.25$422
TG Therapeutics, Inc.16$352
Merz Pharmaceuticals, LLC9$266
Argenx US, Inc.11$259
Bristol Myers Squibb16$251
Mallinckrodt Hospital Products Inc.9$208
Neurelis, Inc.8$191
E.r. Squibb & Sons, L.L.C.11$169
Alnylam Pharmaceuticals Inc.7$140
Johnson & Johnson8$137
Impel Pharmaceuticals Inc.8$133
Livanova USA, Inc.5$130
Axsome Therapeutics, Inc.4$126
Tanabe Pharma America, Inc.7$117
Grifols USA, LLC4$117
Nevro Corp.7$99
Otsuka America Pharmaceutical, Inc.4$99
Banner Life Sciences, LLC3$79
Genentech USA, Inc.4$78
Adamas Pharmaceuticals, Inc.3$68
Avanir Pharmaceuticals, Inc.5$65
Vertical Pharmaceuticals, LLC2$58
ZOLL Respicardia, Inc.1$57
Catalyst Pharmaceuticals, Inc.3$48
Avadel CNS Pharmaceuticals, LLC2$47
Ipsen Biopharmaceuticals, Inc1$32
Avion Pharmaceuticals2$31
Averitas Pharma Inc.1$24
Abbott1$16
Ultragenyx Pharmaceutical Inc.1$16
Elutia, Inc.1$16
Resmed Corp1$15
GE HealthCare1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,747 in reported general payments places this provider in the 85th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$224,980
Medicare patients
1,165
Services billed
2,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl13$206,393
VumerityDiroximel Fumarate11$96,835
Aimovig AutoinjectorErenumab-Aooe103$80,388
NuplazidPimavanserin Tartrate16$80,051
Emgality PenGalcanezumab-Gnlm58$42,088
NourianzIstradefylline20$40,631
UbrelvyUbrogepant30$37,436
AptiomEslicarbazepine Acetate22$36,293
XcopriCenobamate23$27,335
BriviactBrivaracetam17$22,810
Emgality SyringeGalcanezumab-Gnlm12$20,607
Nurtec OdtRimegepant Sulfate11$16,633
QuliptaAtogepant14$14,425
NeuproRotigotine13$10,255
Levetiracetam206$8,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$499$206,39313 claims
BiogenVumerity$2,012$96,83511 claims
Acadia Pharmaceuticals IncNuplazid$569$80,05116 claims
AbbVieUbrelvy, Qulipta$1,802$51,86144 claims
Kyowa Kirin, Inc.Nourianz$956$40,63120 claims
UCB, Inc.Briviact, Neupro$1,341$33,06530 claims
SK Life Science, Inc.Xcopri$1,326$27,33523 claims
PfizerNurtec Odt$5,937$16,63311 claims
Upsher-smith Laboratories LLCTopiramate$581$1,855216 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$1,120$1,51829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 neurology providers in Arkansas.

Other neurology in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →